Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize Antibody D93
Start of Phase 1 Clinical Trial Planned for the Second Half of This Year
20-Mar-2007 -
Micromet, Inc. and TRACON Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of products for cancer treatment, announced an agreement granting TRACON exclusive worldwide rights to develop and commercialize Micromet's D93 antibody with a novel mode of ...
angiogenesis
antibodies
clinical trials
+4